CTLA4 and colorectal carcinoma: The second trial, not yet recruiting, will explore the efficacy of the combination of Monalizumab and MEDI5752 (a bispecific antibody that targets both PD-1 and CTLA-4) in metastatic dMMR/MSI solid tumors, including CRC (NCT06152523).